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Aim: To analyze the survival of patients with breast cancer (BC) depending on age, molecular subtype of the tumor and the presence 
of metabolic syndrome. Patients and Methods: We have analyzed the results of examination and treatment of 202 patients with 
BC of stages I–III. The patients were distributed by age into 2 groups. The group 1 included 86 elderly patients (from 65 to 84 years 
old), the group 2 — 116 younger patients (from 32 to 64 years). An overall 1-, 3- and 5-year survival rates of the treated patients 
were assessed. The significance of factors influencing the overall survival (OS) of patients with BC was determined using the 
methods of statistical analysis. Results: Molecular subtype of BC significantly affects survival rates: in a case of a luminal B sub-
type the 5-year OS was 71.6% vs 80% (p < 0.05) in groups 1 and 2, respectively while in a case of a basal-like subtype it was 
60.2% and 71.6% (p < 0.05). The presence of metabolic syndrome significantly reduced the 5-year OS (up to 70.7% and 80.6%, 
p < 0.05 in groups 1 and 2, respectively). Conclusion: The OS is lower in elderly patients with BC compared with younger patients, 
especially in those who suffer from metabolic syndrome.
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Breast cancer (BC) occupies the first place in the 
structure of cancer-related morbidity and mortality 
in women in Ukraine, as well as in countries of Europe 
and America. The number of new cases in the world 
exceeds 1 million per year. The statistical data show 
that in the economically developed countries there 
is a stable increase in the incidence and mortality 
caused by BC. Over the past 30 years the number 
of BC cases has increased by more than 20%, and 
mortality by 11% [1].
In Ukraine, according to the National Cancer 
Registry, in 2016 the incidence of BC and mortality 
from this disease amounted respectively 64.6 and 
29.3 cases per 100 thousand female population. 
The highest incidence of BC is observed in the age 
range of 65–69 years — 170.3 cases per 100 thou-
sand population, whereas in the next 10 years (age 
range 70–79 years) the number of patients with 
BC decreases yielding 88.3 cases per 100 thousand 
people [2].
According to the classification of the World 
Health Organization (2012), there are the follow-
ing age ranges: young age (25–44 years), middle 
age (45–59 years), elderly age (60–75 years), old 
age (76–90 years)) and long-livers (more than 
90 years) [3]. Exactly in elderly and old women there 
are disturbances in the fat and carbohydrate balance, 
cardiovascular diseases (hypercholesterolemia, hy-
pertension, type II diabetes, insulin resistance, etc.), 
which may precede the onset of BC. According to the 
literature data [4, 5], the metabolic syndrome (MS) 
is an integral indicator of concomitant disease in pa-
tients with BC. This syndrome includes a complex 
of disorders of carbohydrate and fat metabolism that 
manifest itself by central obesity, diabetes mellitus, 
lipid metabolism disorders, arterial hypertension. The 
MS suppresses immunological reactivity, antitumor 
resistance, and induces an additional comorbidity, 
including cardiovascular and renal pathology. In view 
of the above, the MS can also affect the overall sur-
vival (OS) rate in patients with BC.
The aim of this study was to conduct a comparative 
analysis of the 1–5-year OS rate of patients with locally 
advanced BC in the groups of elderly and younger 
patients, depending on the clinical-morphological and 
immunohistochemical features of the tumors and the 
presence of MS.
MATERIALS AND METHODS
In the study, we have analyzed the results of com-
plex clinical examination and treatment of 202 pa-
tients with BC of I–III stages treated at the Kyiv 
Regional Cancer Dispensary (KRCD) in 2009–2015. 
The stage of the tumor process was established ac-
cording to the TNM classification (7th edition). All pa-
tients underwent laboratory, clinical and radiological 
examinations; an analysis of the histological structure 
of the removed tumors, the expression of molecular 
biological markers (hormonal receptors (estrogen re-
ceptor (ER), progesterone receptor (PR), epidermal 
growth factor receptor HER2/neu) for the establish-
ment of the molecular BC subtype according to ap-
proved protocols for examination in patients with BC.
On the basis of the results of treatment and clini-
cal monitoring of the patients, the 1-, 3-, and 5-year 
OS of patients depending on the age of patients, tumor 
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size, metastasis in lymph nodes, molecular subtypes 
of tumors, and the presence of MS were analyzed. 
Complex treatment was performed for all patients: 
surgical treatment — radical mastectomy according 
to Madden, adjuvant radiotherapy for lymphatic outflow 
routes (median focal dose of irradiation was 46 Gy) 
and adjuvant polychemotherapy (6 courses according 
to the CAF scheme: endoxan 600 mg/m², 5-fluorouracil 
600 mg/m², doxorubicin 60 mg/m²). The treatment 
of patients was carried out in accordance with the local 
standards for treatment of patients with BC, provided 
in the KRCD in 2009–2015, guided by the methodologi-
cal recommendations of the National Cancer Institute 
in 2008–2015. Patients who did not receive full treatment 
due to poor performance status were not included in our 
study. All patients provided informed written consent 
for participation in the research and the use of their 
personal data for scientific purposes.
An assessment of the 1-, 5-year OS of the treated 
patients and determination of the factors that affect 
this index were carried out using statistical methods 
for survival analysis. The comparison of the ob-
tained data was carried out using the Cox test and 
Wilcoxon — Gehan method. For statistical analysis 
of the data, Microsoft Excel and STATISTICA 9 for 
Windows XP were used. The differences between the 
groups were considered to be significant at p < 0.05.
RESULTS AND DISCUSSION
The survey involved 202 patients with BC, including 
a significantly higher number of patients with stage II 
(n = 152) and stage III (n = 36) than stage I (n = 14). 
All patients were distributed by age into 2 groups. The 
group 1 included 86 patients (42.6%) with the age from 
65 to 84 years, and the group 2 included 116 patients 
(57.4%) with the age from 32 to 64 years. We have 
chosen such age groups because it is known that the 
risk of BC development is 150 times higher for women 
older than 65 years compared with those younger than 
30 [6]. To study the factors that affect the OS of elderly 
patients, we conducted an analysis of OS, depending 
on a number of clinical, molecular-biological charac-
teristics of tumors and the presence of concomitant 
pathology. In particular, in these age groups we have 
analyzed the following important parameters which af-
fect the survival rates: 1) the size of the primary tumor 
and regional lymph metastasis; 2) molecular subtype 
of the tumors; and 3) the impact of MS.
The effect of the size of the primary tumor and re-
gional lymph metastasis on the survival rates of the 
patients with BC. The size of the primary tumor and me-
tastasis in regional lymph nodes are the most important 
factors for the prognosis of the disease course [7]. Me-
tastases in 4 or more regional lymph nodes significantly 
increase the risk of distant metastasis [8]. An analysis 
of the size of the tumors and metastatic lesions in regional 
lymph nodes showed the following: in group 1 the aver-
age diameter of the tumors was 2.86 ± 0.67 cm, in group 
2 — 2.71 ± 0.71 cm, that is, there was no significant 
difference. The size of tumors up to 2.2 cm in diam-
eter was noted in 2 (2.3%) patients from group 1 and 
in 6 (5.1%) patients from group 2. The diameter of the 
tumors from 2 to 5 cm was detected in 35 (40.7%) and 
59 (50.9%) patients of the groups 1 and 2, respectively, 
more than 5 cm in diameter — in 49 (57.1%) of pa-
tients from group 1 and 51 (44%) of the patients from 
group 2 (Table 1).
Table 1. Clinical and biological features of tumors in patients from 
group 1 and group 2
Parameters
Group 1
65–78 years 
old, n/%
(n = 86/100%)
Group 2
32–64 years 
old, n/%
(n = 116/100%)
Mean age, years 70.6 ± 6.7 47.3 ± 9.2
Mean tumor size, cm
< 2
2–5
> 5
2.86 ± 0.67
2/2.3*
35/40.7
49/57.0*
2.71 ± 0.71
6/5.1
59/50.9
51/44.0
Metastases to regional lymph nodes 
are absent 27/31.4 48/41.4
Frequency of lymph nodes metasta-
ses, total:
1–4 lymph nodes
5–8 lymph nodes
59/68.6
43/50.0
16/18.6*
68/58.6
57/49.1
11/9.5
Molecular subtype of BC:
luminal A
luminal B
basal-like
39/45.3*
32/37.2
15/17.5*
45 /38.8
41/35.3
30/25.9
Note: *The difference between the groups is significant, p < 0.05.
In patients from group 1, the incidence of lymph node 
metastases was higher than in group 2 (68.6% vs 58.6%) 
with a greater number of affected lymph nodes (5–8), the 
frequency of which was 18.6% vs 9.5%.
In the analysis of OS of patients from groups 
1 and 2 depending on the size of the tumors, we estab-
lished the following: with tumor size < 5 cm, the OS of pa-
tients from both groups was equal (100%), the 3-year 
OS in patients from group 1 compared with group 2 was 
80.1% vs 88.7%, and the 5-year OS in elderly patients 
was 73.4%, whereas in group 2 it amounted to 84.1%.
It was found that in patients from group 1, the 
OS rates were lower than in group 2. In particular, the 
1- and 5-year OS of patients from group 1 compared 
with group 2 were 93.3% vs 95.1% (p > 0.05); and 
57.3% vs 70.0% (p < 0.05), respectively.
A comparative analysis of the survival depending 
on metastasis in regional lymph nodes (Fig. 1) showed 
that in elderly and young patients without lymph 
node involvement, the 1-year OS was high (95.5% 
and 100%, respectively). The 3-year OS under the 
same conditions in patients from group 1 was 88.9%, 
in patients from group 2 it was higher and amounted 
to 95.6%. The 5-year OS in elderly patients was signifi-
cantly lower than in young patients (81.3% vs 88.5%).
With a metastatic lesions in 1–4 regional lymph 
nodes, the 1-year OS was lower than in patients with-
out metastases in the lymph nodes, and was 91.2% and 
96% in the groups 1 and 2, respectively, whereas the 
3-year OS of patients from groups 1 and 2 was 77.8% 
and 88.4%, respectively, and the 5-year OS in these 
groups was 68.6% vs 79.3% (Table 2). So, OS in el-
derly patients with tumors < 5 cm and with metasta-
ses in 1–4 lymph nodes was significantly lower than 
in young patients.
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Fig. 1. The curves of the 1-, 3- and 5-year OS of patients from 
groups 1 and 2 with metastases in 1–4 lymph nodes; Kaplan — 
Mayer curve (p = 0.005 by Cox criterion)
Table 2. OS of the elderly patients (group 1, ≥ 65 years) and young-
er patients (group 2, < 65 years) depending on the clinical characteristics 
of the tumor process
Clinical characteristics of the tumor process 
and the number of patients in the groups
OS, %
1-year 3-year 5-year
Tumor size 2–5 cm Group 1 (n = 35) 100.0 80.1 73.4
Group 2 (n = 59) 100.0 88.7 84.1*
Regional lymph node metas-
tases are absent
Group 1 (n = 27) 95.5 88.9 81.3
Group 2 (n = 48) 100.0 95.6 88.5
Metastases in 1–4 lymph 
nodes
Group 1 (n = 43) 91.2 77.8 68.6
Group 2 (n = 57) 96.0 88.4 79.3*
Note: *The difference between the groups 1 and 2 is significant, p < 0.05.
Relation between survival rates and molecular 
subtype of BC. Clinical and morphological cha-
racteristics of the tumor are not sufficiently precise 
to predict the course and prognosis of the disease, 
therefore, the molecular characteristics of tumors, 
i.e. expression of molecular biological markers 
in tumor cells, is of high importance [9]. Differences 
in the expression levels of certain markers could help 
to explain why the tumors with similar prevalence and 
histological structure differ in aggression and the 
disease course. According to the molecular genetic 
classification, all malignant tumors of the mammary 
gland by their biological characteristics are classified 
into the following subtypes: luminal A, luminal B, and 
triple-negative or basal-like BC [10, 11].
Analysis of the expression of hormonal receptors 
(ER and PR) and Her-2/neu in BC cells showed that 
luminal A subtype predominated in the patients from 
group 1 (39/45.3%), but not in group 2 (45/38.8%) 
(p < 0.05). Luminal B subtype was detected 
in almost the same number of patients from 
the groups 1 and 2 (32 (37.2%) patients and 
41 (35.3%) patients, respectively). Basal-like sub-
type of BC in group 1 was determined less frequently 
than in group 2 (15 (17.5%) patients and 30 (25.9%) 
patients, respectively).
We have analyzed the 1-, 3-, 5-year OS rates in elderly 
with different molecular genetic types of BC (Table 3, 
Fig. 2). The 1-year OS rate in patients with luminal and 
young patients type A tumors of groups 1 and 2 was 
almost identical (97.1% and 97.7%, respectively), while 
the 3- and 5-year OS of patients from group 1 were lower 
than in patients from group 2 (81.2% vs 90.7%, and 
78.4% vs 82.4%, respectively). The 1-year OS of patients 
with luminal B subtype from groups 1 and 2 was also 
nearly identical and amounted to 92.1% and 94.6%, 
respectively. The 3-year OS of patients from group 1 was 
84.1%, in patients from group 2 — 88.6%. The 5-year 
OS of elderly patients was 71.6%, and young patients — 
80%. The 1-year OS in patients with basal-type BC from 
groups 1 and 2 was 87.5% and 90.2%, respectively. The 
3-year OS of patients from group 1 was 77.4%, patients 
from group 2 — 86.1%. The 5-year OS in elderly patients 
was 60.2%, and in young patients — 71.6%.
Table 3. OS rate in elderly (group 1) and younger (group 2) patients with 
BC of different molecular subtypes
Molecular subtype Groups and num-ber of patients
OS, %
1-year 3-year 5-year
Luminal А Group 1 (n = 39) 97.1 81.2 78.4
Group 2 (n = 45) 97.7 90.7 82.4
Luminal B Group 1 (n = 32) 92.1 84.1 71.6
Group 2 (n = 41) 94.6 88.6 80.0*
Basal-like Group 1 (n = 15) 87.5 77.4 60.2
Group 2 (n = 30) 90.2 86.1 71.6*
Note: *The difference between the groups 1 and 2 is significant, p < 0.05.
Basal-like subtype
O
S
Observation period, months
   Group 1                     Group 2
Fig. 2. The curves of the 1-, 3- and 5-year OS of patients from 
groups 1 and 2 with basal-like subtype; Kaplan — Mayer curve 
(p = 0.005 by Cox criterion)
Thus, the tendency towards worsening of the 
OS rates was found in all molecular BC subtypes, 
but significantly lower OS rates were observed in el-
derly patients with luminal B and basal-like molecular 
BC subtypes compared to young patients. Our data 
are in agreement with the data of other authors on the 
unfavorable course of the tumor process in the case 
of luminal B and the basal-like BC subtypes [12].
The impact of MS in survival rates of BC pa-
tients. We have analyzed the clinical and biological 
features of BC in elderly and young patients de-
pending on the presence or absence of MS. In the 
group 1 of patients MS was diagnosed in 46 (53.5%) 
out of 86 patients, in the group 2 — in 48 (41.4%) out 
of 116 patients. The main characteristics of the tumor 
process in patients with MS are given in Table 4. The 
patients with MS, compared with patients without MS, 
were older, had lower number of tumors < 2 cm and 
higher number of tumors > 5 cm, a higher rate of lymph 
nodes metastasis (24.0% vs 14.6%), a higher fre-
quency of luminal B subtype (47.8% vs 41.7%).
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Table 4. Clinical and biological characteristics of tumors in elderly 
and young adult patients with MS
Parameters
Group 1 with MS
65–78 years old, 
n/%
(n = 46/100%)
Group 2 with MS
32–64 years old, 
n/%
(n = 48/100%)
Mean age, years 72.2 ± 5.3* 50.6 ± 7.5
Mean tumor size, cm
< 2
2–5
> 5
2.91 ± 0.87
2/4.3*
19/41.3
25/54.4*
2.85 ± 0.79
6/12.5
22/45.8
20/41.7
Metastases to regional lymph nodes 
are absent 10/21.7 14/29.2
Frequency of lymph node metasta-
ses, total:
1–4 lymph nodes
5–8 lymph nodes
25/54.3
11/24.0*
27/56.2
7/14.6
Molecular subtype of BC:
luminal A
luminal B
basal-like
16/34.8
22/47.8*
8/17.4
18/37.5
20/41.7
10/20.8
Note: *The difference between the groups is significant, p < 0.05.
Next, we have analyzed the impact of MS on survival 
of BC patients of different age. The analysis of 1-, 3- and 
5-year OS of all BC patients (elderly and young) with and 
without MS (Fig. 2) has shown that the 1-year OS in pa-
tients with MS was slightly lower than in patients without 
MS and amounted to 92.5% and 96.8%, respectively. 
The 3-year OS of patients with MS was 82.9%, in pa-
tients without MS — 84.6%, and the 5-year OS were 
70.7% and 80.6%, respectively (Table 5). Consequently, 
1-, 3-, and 5-year OS in BC patients with MS was lower 
than in patients without MS, but statistically significant 
differences were detected regarding only 5-year sur-
vival rates, which confirms the data of other research-
ers [13, 14]. So, OS in elderly and young patients with 
MS was significantly lower than in patients without 
MS. The indexes of OS in elderly and young patients 
with and without MS, depending on clinical and mor-
phological and immunohistochemical characteristics 
of tumors are presented in Table 6.
Table 5. The OS of the elderly (group 1) and younger (group 2) patients 
depending on the presence (+) or absence (–) of the MS
Groups and number 
of patients
MS,
«+» / «–»
OS, %
1-year 3-year 5-year
Group 1
≥ 65 years
n = 38 + 92.5 82.9 70.7
n = 48 – 96.8 84.6 80.6*
Group 2
< 65 years
n = 70 + 90.4 82.7 74.2
n = 46 – 98.2* 88.6 87.7*
Note: *The difference between the groups with and without MS is signifi-
cant, p < 0.05.
Table 6. The OS of the elderly (group 1) and young (group 2) patients 
with or without MS depending on molecular BC subtype
Molecular BC subtype Groups of patients OS, %1-year 3-year 5-year
Luminal А Group 1, MS + 95.2 80.2* 75.5*
Group 1, МS – 98.3 87.4 85.8
Group 2, МS + 96.7 90.2 80.3**
Group 2, МS – 98.8 94.1 84.7
Luminal В Group 1, МS + 94.8* 78.3* 72.5**
Group 1, МS – 100 86.2 80.2
Group 2, МS + 90.4* 83.6 78.4**
Group 2, МS – 100 88.9 86.7
Basal-like Group 1, МS + 92.7 76.5* 68.1**
Group 1, МS – 95.1 84.3 77.4
Group 2, МS + 89 * 77.2* 70.6**
Group 2, МS – 97.1 87.8 72.1
Notes: *The difference between the subgroups with and without MS of group 1 is sig-
nificant, p < 0.05. **The difference between the subgroups with and without 
MS of group 2 is significant, p < 0.05.
The analysis of OS in elderly patients with and 
without MS depending on the size of the tumors 
showed the following (Table 7): if tumors were < 5 cm, 
the 1-year OS of elderly patients with MS was 95%, 
without MS — 100%. The 3-year OS of patients from 
group 1 with MS was 77.1%, in patients without 
MS — 83.4%. The 5-year OS in BC patients with and 
without MS was 68.4%, in young patients — 76.5%. 
In young patients with and without MS, and with 
tumors < 5 cm were as follows: 1-year OS — 97.4% 
and 100%; 3-year OS — 80.9% and 91.7%; 5-year 
OS — 79.5% and 84.9%, respectively. The OS rate 
in the elderly patients without metastasis in lymph 
nodes and with and without MS was as follows: 1-year 
OS of patients with MS — 95.5% and without MS — 
97.3%; 3-year OS of patients with MS was 85.1%, 
patients without MS — 93.4%; the 5-year OS was 
79.2% and 84.3%, respectively. In young patients 
with and without MS, in the absence of affected lymph 
nodes OS values were as follows: 1-year OS — 96.7% 
and 100%; 3-year OS — 92.5% and 95.6%; 5-year 
OS — 90.1% and 92.7%, respectively. In elderly 
patients with metastases in 1–4 lymph nodes with 
MS without MS, the 1-year OS rate was 92.4% and 
100%; the 3-year OS — 70.5% and 80.9%; and the 
5-year OS in patients 60.6% and 72.2%, respectively. 
OS of young patients with metastases in 1–4 lymph 
nodes with and without MS was as follows: the 
1-year OS 95,6% and 100%; the 3-year OS 80.3% 
and 93.8%; and the 5-year OS 71.5% and 86.4%, 
respectively.
Based on comparisons of OS values in elderly and 
young patients with MS and without MS, it can be con-
cluded that MS affects the course of the disease, 
reducing OS, especially in older women with a more 
widespread tumor process, especially in women 
with metastases in 1–4 lymph nodes. However, the 
effect of MS on OS most significantly increased after 
36 months of observation. Thus, our data are in ac-
cordance with the data of many authors [7, 10, 14, 15], 
concerning the negative impact of concomitant pathol-
ogy on the course and prognosis of the tumor process.
To study the effect of MS on the OS rates, the in-
dexes of OS in elderly and young patients with different 
Table 7. The OS of the elderly (group 1) and young (group 2) patients 
with (+) or without (–) MS depending on clinical characteristics of tumor 
process
Clinical characteristics of the tumor process
and groups of patients
OS,%
1-year 3-year 5-year
Tumor size < 5 см Group 1, МS + 95* 77.1 68.4*
Group 1, МS – 100 83.4 76.5
Group 2, МS + 97.4 80.9 79.5**
Group 2, МS – 100 91.7 84.9
Regional lymph node 
metastases are absent
Group 1, МS + 95.5 85.1 79.2*
Group 1, МS – 97.3 93.4 84.3
Group 2, МS + 96.7 92.5** 90.1
Group 2, МS – 100 95.6 92.7
Metastases  
in 1–4 regional lymph 
nodes
Group 1, МS + 92.4* 70.5* 60.6*
Group 1, МS – 100 80.9 72.2
Group 2, МS + 95.6* 80.3** 71.5**
Group 2, МS – 100 93.8 86.4
Note: *The difference between the subgroups with and without MS of group 1 is sig-
nificant, p < 0.05. **The difference between the subgroups with and without 
MS of group 2 is significant, p < 0.05.
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molecular subtypes of tumors in patients with MS and 
without MS were analyzed (Table 6, Fig. 3). The 1-year 
OS of elderly patients with luminal A subtype with and 
without MS was 95.2% and 98.3%, the 3- and 5-year 
OS were 80.2% and 87.4%; and 75.5% and 85.8%, 
respectively. The 1-year OS of elderly patients with 
luminal B subtype with MS and without MS was 94.8% 
and 100%, the 3-year OS — 78.3% and 86.2%, and the 
5-year OS — 72.5% and 80.2%, respectively (Fig. 3). 
The 1-year OS of elderly patients with basal-like sub-
type with MS and without MS was 92.7% and 95.1%, 
the 3-year OS — 76.5% and 84.3%, and the 5-year 
OS — 68.1% and 77.4%, respectively (Fig. 4).
The 1-year OS of young patients with luminal 
A subtype with MS and without MS was 96.7% and 
98.8%, the 3-year OS — 90.2% and 94.1%, the 5-year 
OS — 80.3% and 84.7%, respectively.
The 1-year OS in young patients with luminal B sub-
type with MS and without MS was 90.4% and 100%, 
the 3-year OS — 83.6% and 88.9%, the 5-year OS — 
78.4% and 86.7%, respectively. The 1-year OS rate 
in young patients with basal-like subtype with MS and 
without MS was 89% and 97.1%, the 3-year OS — 
77.2% and 87.8%, the 5-year OS — 70.6% and 72.1%.
The comparison of OS values in the groups allows 
conclude that the worst OS rate was observed in the 
elderly patients with basal-like BC subtype, which 
is in accordance with the opinion of many authors 
regarding the unfavorable prognosis of basal-type 
tumors [16] and the unfavorable effects of concomitant 
pathology on the course of the tumor process.
It’s evident that elderly patients more often suffer 
from different concomitant pathologies [17]. In par-
ticular, in elderly patients with BC, there are prevalent 
the diseases of the organs of the cardiovascular and 
musculoskeletal systems, carbohydrate metabolism 
disorders, liver and gallbladder pathologies, while 
in the anamnesis of young patients more often are 
documented benign tumors and dyshormonal hyper-
plasia of the mammary glands, and ovarian cysts [18]. 
That’s why lower OS in elderly patients with BC could 
be explained by the use of less intensive methods 
of local treatment, a decreased number of polyche-
motherapy cycles and a reduction in the dosage 
of anticancer drugs, since in this group of patients the 
concomitant pathology interferes with therapeutic in-
terventions [19]. However, in our study, all patients with 
BC received a comprehensive treatment at standard 
doses, because the patients with concomitant pathol-
ogy which contraindicated for complex treatment, were 
not included in our study.
CONCLUSION
In conclusion, in elderly patients with BC we have 
revealed a statistically significant difference in the 1-, 
3- and 5-year OS rates compared to young patients, 
namely, in patients with tumor sizes up to 5 cm, with 
metastatic lesions in 1–4 lymph nodes, and with lumi-
nal B and basal-like BC subtypes. The OS rates were 
significantly lower in patients with MS compared to the 
patients without MS, especially in elderly patients.
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